Boceprevir versus placebo with pegylated interferon alfa-2b and ribavirin for treatment of hepatitis C virus genotype 1 in patients with HIV: a randomised, double-blind, controlled phase 2 trial

M. Sulkowski; S. Pol; J. Mallolas; H. Fainboim; C. Cooper; J. Slim; A. Rivero; C. Mak; S. Thompson; A.Y. Howe; L. Wenning; P. Sklar; J. Wahl; A.I.M. Hoepelman; x P05411 Study Investigators; W. Greathouse

Boceprevir versus placebo with pegylated interferon alfa-2b and ribavirin for treatment of hepatitis C virus genotype 1 in patients with HIV: a randomised, double-blind, controlled phase 2 trial

Translated title of the contribution: Boceprevir versus placebo with pegylated interferon alfa-2b and ribavirin for treatment of hepatitis C virus genotype 1 in patients with HIV: a randomised, double-blind, controlled phase 2 trial

M. Sulkowski, S. Pol, J. Mallolas, H. Fainboim, C. Cooper, J. Slim, A. Rivero, C. Mak, S. Thompson, A.Y. Howe, L. Wenning, P. Sklar, J. Wahl, A.I.M. Hoepelman, x P05411 Study Investigators, W. Greathouse

Research output: Contribution to journal › Article › Academic › peer-review

Translated title of the contribution	Boceprevir versus placebo with pegylated interferon alfa-2b and ribavirin for treatment of hepatitis C virus genotype 1 in patients with HIV: a randomised, double-blind, controlled phase 2 trial
Original language	Undefined/Unknown
Pages (from-to)	597-605
Number of pages	9
Journal	The Lancet Infectious Diseases
Volume	13
Issue number	7
Publication status	Published - 2013

Access to Document

http://www.ncbi.nlm.nih.gov/pubmed/23768747

Cite this

Sulkowski, M., Pol, S., Mallolas, J., Fainboim, H., Cooper, C., Slim, J., Rivero, A., Mak, C., Thompson, S., Howe, A. Y., Wenning, L., Sklar, P., Wahl, J., Hoepelman, A. I. M., P05411 Study Investigators, X., & Greathouse, W. (2013). Boceprevir versus placebo with pegylated interferon alfa-2b and ribavirin for treatment of hepatitis C virus genotype 1 in patients with HIV: a randomised, double-blind, controlled phase 2 trial. The Lancet Infectious Diseases, 13(7), 597-605. http://www.ncbi.nlm.nih.gov/pubmed/23768747

@article{2c4d5c6af88e48e59374cf6890876764,

title = "Boceprevir versus placebo with pegylated interferon alfa-2b and ribavirin for treatment of hepatitis C virus genotype 1 in patients with HIV: a randomised, double-blind, controlled phase 2 trial",

author = "M. Sulkowski and S. Pol and J. Mallolas and H. Fainboim and C. Cooper and J. Slim and A. Rivero and C. Mak and S. Thompson and A.Y. Howe and L. Wenning and P. Sklar and J. Wahl and A.I.M. Hoepelman and {P05411 Study Investigators}, x and W. Greathouse",

year = "2013",

language = "Undefined/Unknown",

volume = "13",

pages = "597--605",

journal = "The Lancet Infectious Diseases",

issn = "1473-3099",

publisher = "Lancet Publishing Group",

number = "7",

}

Sulkowski, M, Pol, S, Mallolas, J, Fainboim, H, Cooper, C, Slim, J, Rivero, A, Mak, C, Thompson, S, Howe, AY, Wenning, L, Sklar, P, Wahl, J, Hoepelman, AIM, P05411 Study Investigators, X & Greathouse, W 2013, 'Boceprevir versus placebo with pegylated interferon alfa-2b and ribavirin for treatment of hepatitis C virus genotype 1 in patients with HIV: a randomised, double-blind, controlled phase 2 trial', The Lancet Infectious Diseases, vol. 13, no. 7, pp. 597-605. <http://www.ncbi.nlm.nih.gov/pubmed/23768747>

Boceprevir versus placebo with pegylated interferon alfa-2b and ribavirin for treatment of hepatitis C virus genotype 1 in patients with HIV: a randomised, double-blind, controlled phase 2 trial. / Sulkowski, M.; Pol, S.; Mallolas, J. et al.
In: The Lancet Infectious Diseases, Vol. 13, No. 7, 2013, p. 597-605.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - Boceprevir versus placebo with pegylated interferon alfa-2b and ribavirin for treatment of hepatitis C virus genotype 1 in patients with HIV: a randomised, double-blind, controlled phase 2 trial

AU - Sulkowski, M.

AU - Pol, S.

AU - Mallolas, J.

AU - Fainboim, H.

AU - Cooper, C.

AU - Slim, J.

AU - Rivero, A.

AU - Mak, C.

AU - Thompson, S.

AU - Howe, A.Y.

AU - Wenning, L.

AU - Sklar, P.

AU - Wahl, J.

AU - Hoepelman, A.I.M.

AU - P05411 Study Investigators, x

AU - Greathouse, W.

PY - 2013

Y1 - 2013

M3 - Article

SN - 1473-3099

VL - 13

SP - 597

EP - 605

JO - The Lancet Infectious Diseases

JF - The Lancet Infectious Diseases

IS - 7

ER -